Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $62.03 | $18.66 | 232.47% | 258.44x | 18.71x | 18.95x | 50.80x | 1.22x | $41.15M | 0.75% | $108.58M | 1.23 | $5.47B | 102.19 | ||
| CORT | CORCEPT THERAPEUTICS INC | $66.65 | $19.23 | 246.61% | 144.89x | 127.29x | 9.05x | 11.21x | 1.36x | $119.79M | 1.72% | $637.99M | 6.11 | $7.06B | -1,027.66 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $295.63 | $96.14 | 207.51% | 67.81x | 40.09x | 9.16x | 36.70x | 1.39x | $641.34M | 1.63% | $1.08B | 8.09 | $40.73B | 44.06 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $51.84 | $17.68 | 193.29% | 52.90x | 40.60x | 5.26x | 6.59x | 1.43x | $164.23M | 4.14% | $605.69M | 7.92 | $3.81B | 34.15 | ||
| KRYS | KRYSTAL BIOTECH INC | $306.63 | $97.61 | 214.13% | 39.57x | 37.92x | 21.52x | 7.08x | 1.88x | $237.38M | 2.64% | $1.28B | 43.59 | $8.55B | 39.95 | ||
| ADMA | ADMA BIOLOGICS INC | $7.92 | $10.70 | -25.98% | 11.48x | 7.98x | 3.67x | 4.70x | 0.39x | $107.90M | 5.77% | $390.33M | 1.65 | $1.90B | 8.56 | ||
| HALO | HALOZYME THERAPEUTICS INC | $68.65 | $71.96 | -4.59% | 23.19x | 8.29x | 5.38x | 37.07x | 0.42x | $667.65M | 8.23% | $219.64M | 1.86 | $9.98B | 15.99 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $52.38 | $41.67 | 25.71% | 37.41x | 13.18x | 3.11x | 1.63x | 0.53x | $767.06M | 7.61% | $6.21B | 32.27 | $8.48B | 17.58 | ||
| OMER | OMEROS CORP | $11.07 | $15.84 | -30.13% | 8.52x | -29.07x | 80.22x | -12.65x | 0.43x | -$94.78M | -11.91% | -$63.33M | -0.88 | $1.11B | 12.27 | ||
| RPRX | ROYALTY PHARMA PLC | $53.97 | $40.70 | 32.61% | 28.26x | 10.12x | 9.66x | 3.13x | 0.61x | $2.34B | 9.93% | $9.94B | 22.75 | $39.45B | 33.91 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $10.95 | $16.59 | -34.01% | 5.34x | 23.30x | 5.23x | 3.15x | 0.67x | $56.42M | 8.82% | $205.80M | 3.52 | $552.86M | 3.82 | ||
| VCEL | VERICEL CORP | $34.27 | $9.32 | 267.58% | 79.70x | 71.08x | 5.96x | 4.91x | 1.68x | $47.49M | 2.73% | $356.23M | 7.02 | $1.74B | 42.93 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $6.23 | $2.88 | 116.17% | 89.00x | 52.13x | 3.37x | 82.67x | 0.85x | $47.52M | 4.48% | $13.01M | 0.08 | $1.22B | 22.88 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $235.89 | $97.65 | 141.57% | 29.86x | 26.18x | 17.09x | 4.74x | 1.47x | $122.22M | 2.61% | $997.32M | 50.16 | $5.06B | 22.45 | ||
| ASND | ASCENDIS PHARMA A | $235.26 | $85.49 | 175.20% | 24.93x | 18.94x | 14.35x | 25.45x | 2.32x | $52.94M | 0.36% | $574.09M | 9.24 | $14.99B | 160.78 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $237.56 | $49.74 | 377.56% | 505.45x | 9.20x | 3.31x | 3.29x | 1.73x | $1.30B | 8.83% | $4.53B | 73.22 | $18.46B | 27.35 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.93 | $5.85 | -49.93% | 10.85x | 4.29x | 2.74x | 3.20x | 0.23x | $7.24M | 4.30% | $52.93M | 0.92 | $116.00M | 7.49 | ||
| TECH | BIO-TECHNE CORP | $48.09 | $15.70 | 206.28% | 67.73x | 24.46x | 6.21x | 3.61x | 1.39x | $269.60M | 3.59% | $2.09B | 13.34 | $7.61B | 29.73 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $30.76 | $36.59 | -15.93% | 12.16x | 8.38x | 1.98x | 1.96x | 0.46x | $341.79M | 19.22% | $910.35M | 15.75 | $1.35B | 5.70 | ||
| TGTX | TG THERAPEUTICS INC | $39.20 | $19.00 | 106.30% | 12.17x | 26.12x | 8.08x | 10.29x | 7.96x | -$14.19M | -0.25% | $583.13M | 4.04 | $6.31B | 42.06 | ||
| UTHR | UNITED THERAPEUTICS CORP | $570.75 | $252.41 | 126.12% | 19.49x | 19.64x | 7.83x | 4.11x | 2.06x | $1.02B | 4.10% | $5.90B | 135.66 | $22.95B | 13.39 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.83 | $2.51 | 52.60% | 15.96x | 16.19x | 2.35x | 3.71x | 1.08x | $4.11M | 1.33% | $82.33M | 1.03 | $241.06M | 11.35 | ||
| EXEL | EXELIXIS INC | $50.03 | $31.47 | 58.95% | 16.04x | 15.19x | 5.44x | 6.50x | 1.17x | $917.69M | 7.10% | $1.94B | 7.49 | $12.52B | 11.85 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.32 | $15.20 | 106.02% | 17.30x | 16.28x | 6.41x | 3.78x | 1.96x | $208.13M | 5.43% | $1.01B | 8.28 | $3.08B | 9.19 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $627.74 | $451.93 | 38.90% | 14.75x | 13.28x | 4.38x | 2.09x | 0.96x | $4.11B | 6.30% | $31.42B | 302.15 | $65.56B | 11.41 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $437.22 | $173.20 | 152.43% | 25.70x | 22.35x | 9.09x | 5.73x | 1.83x | $3.71B | 3.34% | $19.36B | 76.20 | $107.46B | 19.93 | ||
| MDXG | MIMEDX GROUP INC | $3.61 | $1.59 | 126.55% | 17.19x | -50.56x | 1.38x | 2.21x | 2.67x | $69.36M | 12.94% | $242.94M | 1.64 | $395.52M | 7.26 | ||
| VCYT | VERACYTE INC | $44.49 | $12.59 | 253.36% | 40.08x | 39.53x | 6.53x | 2.64x | 2.30x | $155.34M | 4.39% | $1.34B | 16.90 | $3.32B | 28.90 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $2.12 | $1.78 | 19.30% | 11.16x | 9.76x | 2.22x | 2.54x | 0.96x | $13.00M | 7.69% | $67.23M | 0.84 | $137.58M | 6.16 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $16.68 | $4.69 | 255.31% | 27.80x | 4.78x | 0.80x | 1.17x | 3.89x | $109.24M | 6.24% | $1.51B | 14.34 | $2.33B | 28.20 | ||
| INCY | INCYTE CORP | $97.34 | $67.49 | 44.22% | 13.35x | 12.36x | 3.62x | 3.46x | 1.18x | $1.45B | 7.48% | $5.62B | 28.21 | $16.02B | 8.56 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.